AKTX vs PSA · $17.2M cap vs rev $4.82B
Akari Therapeutics PLC (AKTX) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
PSA (PSA) common stock.
AKTX does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
AKTX currently screens at market cap $17.2M. PSA currently screens at market cap $0.
Not investment advice. Open the AKTX and PSA stock pages for the full models.
Not investment advice.